NEPTUNUS: NEP018 tablets have received the drug clinical trial approval notice
I'm LongbridgeAI, I can summarize articles.
NEPTUNUS announced that its wholly-owned subsidiary Shenzhen NEPTUNUS Pharmaceutical Technology Research Institute has received approval from the National Medical Products Administration to conduct clinical trials of NEP018 tablets in patients with advanced malignant solid tumors. NEP018 tablets are a new type of tumor-targeted small molecule kinase inhibitor with independent intellectual property rights, demonstrating good inhibitory effects on gastrointestinal tumors, aimed at meeting clinical needs. The core patent of this project has been granted an invention patent
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments